Lakefront Biotherapeutics (LKFT) Depreciation and Depletion (2016 - 2018)

Lakefront Biotherapeutics (LKFT) has reported Depreciation and Depletion for 3 consecutive years, with -$2.7 billion the latest figure, recorded in Q3 2018.

• Quarterly Depreciation and Depletion fell 4.83% year-over-year to -$2.7 billion in Q3 2018, while the trailing twelve-month figure through Sep 2018 was -$2.6 billion (down 50511.93% YoY) and the FY2017 annual result came in at $5.2 million, up 9.36% from the prior year.
• Depreciation and Depletion slipped to -$2.7 billion in Q3 2018 per LKFT's latest filing, from $2.7 billion in the prior quarter.
• Over the last five years, Depreciation and Depletion for LKFT reached as high as $2.7 billion in Q2 2018 and fell as low as -$2.7 billion in Q3 2018.
• A 3-year average of $1.3 million and a median of $1.2 million in 2016 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2017 — Depreciation and Depletion soared 217131.99% — and 2018, when it dropped 4.83%.
• Year by year, Depreciation and Depletion stood at $1.2 million in 2016, then rose by 6.23% to $1.3 million in 2017, then sank by 214255.98% to -$2.7 billion in 2018.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered -$2.7 billion, $2.7 billion, and $1.3 million for Q3 2018, Q2 2018, and Q4 2017 respectively.